MELIORA Virtual Coach Intervention for Breast Cancer Prevention

NCT ID: NCT07200427

Last Updated: 2025-10-01

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

NA

Total Enrollment

2080 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-12-31

Study Completion Date

2027-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Breast cancer (BC) is the most commonly diagnosed cancer in women worldwide, with early-onset cases increasing due to genetic and lifestyle factors. Traditional prevention strategies have shown limited effectiveness, creating the need for innovative approaches. The MELIORA project develops an AI-driven digital tool, the Virtual Coach (VC), to promote sustainable behaviour change in physical activity, diet, and alcohol use. Three randomized-controlled studies will be conducted: MELIORA-HEALTHY (women at risk, n=1080 in Greece, Lithuania, Spain), MELIORA-PATIENTS (women undergoing treatment, n=400 in Lithuania, Spain), and MELIORA-SURVIVORS (post-treatment survivors, n=600 in Lithuania, Spain, Sweden). Participants across diverse regions and backgrounds will be randomized to standard lifestyle advice or the same advice plus the MELIORA VC app. Each study lasts 12 months, with outcomes assessed at baseline, 6, and 12 months. The primary outcome is physical activity, with secondary outcomes including sedentary behaviour, diet, alcohol use, and quality of life. If effective, the MELIORA VC could offer a scalable, cost-effective model for BC prevention and survivorship care, providing valuable evidence to guide public health strategies.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Breast cancer (BC) is the most commonly diagnosed cancer among women worldwide, with early-onset cases rising rapidly due to interactions between genetics and lifestyle behaviours. Traditional efforts to modify these behaviours have had limited success, highlighting the need for innovative, multifaceted approaches. The Multimodal Engagement and Sustainable Lifestyle Interventions Optimizing Breast Cancer Risk Reduction Supported by Artificial Intelligence (MELIORA) project addresses this gap by promoting sustainable behaviour change through an innovative intervention using artificial intelligence (AI). The project will develop and evaluate an AI-driven behaviour change digital solution, the MELIORA virtual coach (VC), designed to enhance awareness, motivation, and promote healthier lifestyle choices related to physical activity, diet, and alcohol consumption, while addressing potential implementation barriers.

The MELIORA VC intervention consists of three separate studies: 1) the MELIORA-HEALTHY Study targeting healthy women at risk of BC (conducted in Greece, Lithuania, Spain), 2) the MELIORA-PATIENTS Study targeting BC patients (conducted in Lithuania, Spain), and 3) the MELIORA-SURVIVORS Study targeting BC survivors (conducted in Lithuania, Spain, Sweden), involving a total of 2,080 participants. The studies will encompass both urban and rural regions and will include participants across the socioeconomic spectrum and/or ethnic minority groups, allowing for the evaluation of how these factors moderate the effectiveness of the MELIORA behavioural change intervention. The studies will follow a randomized-controlled design. For the MELIORA-HEALTHY study, a total of 1080 adult women (360 per site), free of cancer and with at least one behavioural (i.e. low levels of physical activity, unhealthy diet, increased alcohol consumption) or metabolic (i.e. increased BMI) risk factor will be recruited. For the MELIORA-PATIENTS study, a total of 400 adult women diagnosed with BC and currently undergoing treatment (200 per site) will be recruited. For the MELIORA-SURVIVORS study, a total of 600 adult women diagnosed with BC and have completed primary therapy (200 per site) will be recruited.

Participants at each site will be randomly assigned (1:1 allocation) to either the intervention group or the control group. The control group will receive the standard of care that is generic advice for a healthy lifestyle and BC prevention. The intervention group will receive the same generic advice along with the MELIORA VC intervention app. The total study duration for each participant will be 12 months, divided into two six-month periods: the intervention period and the follow-up period. Targeted behaviours will be assessed at three time points: baseline (0 months), end of the six-month intervention period (6 months), and end of the six-month follow-up period (12 months). The primary outcome that will be assessed is physical activity while secondary outcomes include sedentary behaviours, diet, alcohol consumption and health-related quality of life.

The MELIORA project represents an innovative approach to BC prevention by integrating an AI-driven digital health solution into real-world settings. The MELIORA studies highlight the role of technology in promoting sustainable behaviour change to prevent the onset or recurrence of BC. The VC tool that will be developed, tested and evaluated is a key outcome of the MELIORA project and aims to support preventive policies and health promotion guidelines for BC prevention. If successful, the MELIORA VC model could be expanded to other at-risk populations, reinforcing the potential of AI-driven, cost-effective health interventions in cancer prevention. Findings will provide valuable insights for policymakers and healthcare professionals on the feasibility, effectiveness, and cost-effectiveness of AI-supported lifestyle interventions, shaping future public health strategies.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Breast Cancer Prevention

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

The MELIORA RCTs will employ a parallel-group, randomized controlled design with two groups: an intervention group and a control group. The study follows a superiority design, with individual-level randomization and a 1:1 allocation ratio.
Primary Study Purpose

PREVENTION

Blinding Strategy

SINGLE

Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

MELIORA Virtual Coach Intervention (VCI) Group

The intervention group will receive generic advice on a healthy lifestyle and breast cancer (BC) prevention plus access to the full MELIORA VCI app.

Group Type EXPERIMENTAL

MELIORA Virtual Coach Intervention

Intervention Type BEHAVIORAL

Based on baseline assessments, the MELIORA VCI app will prompt intervention group participants to set weekly goals on lifestyle behaviours such as physical activity, diet, alcohol use, and sedentary time, and support daily self-monitoring and step count tracking. Goals will be dynamically adjusted by the virtual coach or the participant to remain realistic and achievable. Τhe app will also offer culturally adapted educational, motivational, and instructional support through mini-courses, tips, recommendations and an embedded library of relevant materials to ensure high adoption rates among women from diverse countries, socioeconomic backgrounds and minority groups. To boost motivation, it will include reminders, gamification features like badges and points, as well as personalized techniques such as action planning, problem solving, social reward, and positive self-talk.

Control Group

The control group will receive the standard of care that is generic advice for a healthy lifestyle and BC prevention.

Group Type PLACEBO_COMPARATOR

Control (generic advice)

Intervention Type OTHER

The control group will receive the standard of care that is generic advice for a healthy lifestyle and BC prevention. A 'light' version of the MELIORA VCI app will be developed to host the control group materials, track participants' step counts, send reminders, and allow scheduling of follow-up visits. No other features will be available in this version of the app.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

MELIORA Virtual Coach Intervention

Based on baseline assessments, the MELIORA VCI app will prompt intervention group participants to set weekly goals on lifestyle behaviours such as physical activity, diet, alcohol use, and sedentary time, and support daily self-monitoring and step count tracking. Goals will be dynamically adjusted by the virtual coach or the participant to remain realistic and achievable. Τhe app will also offer culturally adapted educational, motivational, and instructional support through mini-courses, tips, recommendations and an embedded library of relevant materials to ensure high adoption rates among women from diverse countries, socioeconomic backgrounds and minority groups. To boost motivation, it will include reminders, gamification features like badges and points, as well as personalized techniques such as action planning, problem solving, social reward, and positive self-talk.

Intervention Type BEHAVIORAL

Control (generic advice)

The control group will receive the standard of care that is generic advice for a healthy lifestyle and BC prevention. A 'light' version of the MELIORA VCI app will be developed to host the control group materials, track participants' step counts, send reminders, and allow scheduling of follow-up visits. No other features will be available in this version of the app.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

MELIORA-HEALTHY study participants must meet all of the following criteria in order to be deemed eligible for study participation:

* Reside in Greece, Lithuania, or Spain.
* Be female and at least 18 years of age.
* Have access to and be able to use a smartphone (iOS or Android) compatible with the MELIORA app.
* Be willing and able to use the MELIORA app for the entire study duration.
* Willing to provide informed consent to participate in the study.
* Have at least one of the following behavioural or metabolic risk factors for BC, assessed in a random order (each site may determine the order that is most convenient for them) until eligibility is confirmed. If a risk factor is identified, the subsequent assessments can be skipped:
* Increased alcohol consumption: More than 1 drink per day.
* Increased body mass index (BMI): BMI ≥ 25 kg/m².
* Physical inactivity: Not meeting World Health Organization (WHO) guidelines of at least 150 minutes of moderate-intensity or 75 minutes of high-intensity aerobic exercise per week.
* Suboptimal diet: Low diet quality based on the rapid Prime Diet Quality Score Screener (rPDQS).

MELIORA-PATIENTS study participants must meet all of the following criteria in order to be deemed eligible for study participation:

* Reside in Spain or Lithuania.
* Be female and at least 18 years old.
* Have access to and be able to use a smartphone (iOS or Android) compatible with the MELIORA app.
* Be willing and able to use the MELIORA app for the entire study duration.
* Willing to provide informed consent to participate in the study.
* Have been diagnosed with breast cancer (BC) within the last 6 months and/or currently undergoing treatment (chemotherapy, radiotherapy, immunotherapy, hormone therapy) and/or in active follow-up.

MELIORA-SURVIVORS study participants must meet all of the following criteria in order to be deemed eligible for study participation:

* Reside in Spain, Lithuania, or Sweden.
* Be female and at least 18 years old.
* Have access to and be able to use a smartphone (iOS or Android) compatible with the MELIORA app.
* Be willing and able to use the MELIORA app for the entire study duration.
* Willing to provide informed consent to participate in the study.
* Have completed primary treatment for breast cancer (surgery, chemotherapy, radiotherapy, immunotherapy, targeted therapy, etc.) and currently be in remission.
* Have at least one of the following behavioural or metabolic risk factors for BC, assessed in a random order (each site may determine the order that is most convenient for them) until eligibility is confirmed. If a risk factor is identified, the subsequent assessments can be skipped:
* Increased alcohol consumption: More than 1 drink per day.
* Increased body mass index (BMI): BMI ≥ 25 kg/m².
* Physical inactivity: Not meeting World Health Organization (WHO) guidelines of at least 150 minutes of moderate-intensity or 75 minutes of high-intensity aerobic exercise per week.
* Suboptimal diet: Low diet quality based on the rapid Prime Diet Quality Score Screener (rPDQS).

Exclusion Criteria

MELIORA-HEALTHY study participants will be excluded from study participation if they meet any of the following criteria:

* Inability to provide fully informed consent.
* Inability to understand or communicate in the local language i.e. Greek in Greece, Lithuanian in Lithuania, Spanish in Spain.
* Current or past diagnosis of cancer or other uncontrolled chronic diseases (e.g., cardiovascular disease, diabetes) that affect lifestyle, dietary habits, or communication skills.
* Mental illness or disorders that affect lifestyle, dietary habits, or communication skills.
* Use of medication that affects lifestyle, dietary habits, or communication skills.
* Recreational drug use.
* Pregnancy, lactation, or intention to become pregnant shortly before, during, or after the intervention.
* Participation in another clinical trial or program aimed at promoting behavioural changes or weight loss at the time of recruitment. If subjects already use health-related apps that affect their weight and lifestyle, including dietary habits and physical activity, the research team will ask them to pause their use until the end of the 12-month study period. However, the use of these applications by the participants cannot be controlled.

MELIORA PATIENTS and MELIORA SURVIVORS study participants will be excluded from study participation if they meet any of the following criteria:

* Inability to provide fully informed consent.
* Inability to understand or communicate in the local language (i.e., Lithuanian in Lithuania, Spanish in Spain, Swedish in Sweden), unless appropriate translation support is available to ensure full understanding of study procedures and informed consent.
* Current or past diagnosis of cancer (other than breast cancer, except skin cancer treated with surgery only) or other uncontrolled chronic diseases (e.g., cardiovascular diseases, diabetes) that affect lifestyle, dietary habits, or communication skills.
* Mental illness or disorders that affect lifestyle, dietary habits, and communication skills.
* Use of medication that affects lifestyle, dietary habits, or communication skills.
* Recreational drug use.
* Pregnancy, lactation, or intention to become pregnant shortly before, during, or after the intervention.
* Participation in another clinical trial or program to promote behavioural changes or weight loss during recruitment. Suppose participants are already using health-related apps affecting their weight and lifestyle, including dietary habits and physical activity. In that case, they will be asked to suspend their use until the end of the 12-month study period. However, the research team cannot control the use of these applications by the participants.
* Severe adherence issues with previous treatments that may interfere with compliance with study tasks (subject to the investigator's assessment).
Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

BROSTCANCERFORENINGEN AMAZONA I STOCKHOLMS LAN

UNKNOWN

Sponsor Role collaborator

Karolinska Institutet

OTHER

Sponsor Role collaborator

Instituto de Investigacion Sanitaria INCLIVA

OTHER

Sponsor Role collaborator

FUNDACION PARA LA INVESTIGACION DEL HOSPITAL CLINICO DE LA COMUNITAT VALENCIANA, FUNDACION INCLIVA

UNKNOWN

Sponsor Role collaborator

LIETUVOS SVEIKATOS MOKSLU UNIVERSITETAS

UNKNOWN

Sponsor Role collaborator

PAGALBOS ONKOLOGINIAMS LIGONIAMS ASOCIACIJA

UNKNOWN

Sponsor Role collaborator

SWPS UNIWERSYTET HUMANISTYCZNOSPOLECZNY

UNKNOWN

Sponsor Role collaborator

EUROPEAN FOOD INFORMATION COUNCIL

UNKNOWN

Sponsor Role collaborator

PREDICTBY RESEARCH AND CONSULTING S.L.

UNKNOWN

Sponsor Role collaborator

ETHNIKO KENTRO EREVNAS KAI TECHNOLOGIKIS ANAPTYXIS

UNKNOWN

Sponsor Role collaborator

EXUS SOFTWARE MONOPROSOPI ETAIRIA PERIORISMENIS EVTHINIS

UNKNOWN

Sponsor Role collaborator

RISA SICHERHEITSANALYSEN GMBH

UNKNOWN

Sponsor Role collaborator

BIOASSIST SA

UNKNOWN

Sponsor Role collaborator

EUROPEAN HEALTH MANAGEMENT ASSOCIATION

UNKNOWN

Sponsor Role collaborator

ETICAS DATA SOCIETY

UNKNOWN

Sponsor Role collaborator

Harokopio University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Yannis Manios

Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Yannis Manios, Professor

Role: PRINCIPAL_INVESTIGATOR

Department of Nutrition and Dietetics, School of Health Science & Education, Harokopio University, Athens, Greece

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Harokopio University

Athens, , Greece

Site Status

Lietuvos Sveikatos Mokslų Universitetas (Lsmu)

Kaunas, , Lithuania

Site Status

Pagalbos Onkologiniams Ligoniams Asociacija (Pola L T)

Kaunas, , Lithuania

Site Status

Fundación Para El Fomento de La Investigación Sanitaria Y Biomédica de La Comunitat Valenciana (Fisabio)

Valencia, , Spain

Site Status

INCLIVA - Instituto de Investigación Sanitaria

Valencia, , Spain

Site Status

Bröstcancerföreningen Amazona I Stockholms Län (Amazona)

Stockholm, , Sweden

Site Status

Karolinska Institutet

Stockholm, , Sweden

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Greece Lithuania Spain Sweden

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Yannis Manios, Professor

Role: CONTACT

+30 2109549156

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Yannis Manios, Professor

Role: primary

+302109549156

Gintare Kaliniene

Role: primary

+370868409708

Neringa Ciakiene

Role: primary

9999999999

Ana Molina Barceló

Role: primary

9999999999

Juan Miguel Cejalvo Andújar

Role: primary

9999999999

Linda Engström

Role: primary

+46730620826

Ioannis Ioakeimidis

Role: primary

9999999999

Related Links

Access external resources that provide additional context or updates about the study.

https://melioraproject.eu/

MELIORA website link

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

101136791

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.